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OBJECTIVES: To assess the clinical and economic burden of gastroesophageal 
reflux disease (GERD) in the U.S. veteran population. METHODS: Patients 
diagnosed with GERD (International Classification of Diseases, Ninth Revision, 
Clinical Modification [ICD-9-CM] codes: 309.81, 530.1, 530.10-530.12, 530.81, 787.1) 
were included in a retrospective study (1/1/2006-5/31/2012) conducted using the 
Veterans Health Administration (VHA) Medical SAS Datasets. Continuous 
medical and pharmacy benefits were required 12-month pre- and 12-month 
post-index date (initial GERD diagnosis date). Comorbidities were examined for 
the 12 months baseline period; medication and treatment were examined during 
the 60-day follow-up period. Health care resource utilization and costs were 
assessed for the 12-month follow-up period. Descriptive statistics were 
calculated as means±standard deviation (SD) and percentages to measure 
treatment, cost, and utilization distribution in the sample. RESULTS: A total of 
1,123,133 GERD patients were identified in the database. During the 12-month 
baseline period, the most common comorbidities were unspecified essential 
hypertension (23.92%), diabetes (13.70%) and hyperlipidemia (8.36%). During the 
60 days post-index date, the most commonly prescribed medications were 
omeprazole (39.87%), simvastatin (27.52%), lisinopril (19.11%), ranitidine 
hydrochloride (12.48%), and hydrochlorothiazide (10.30%). During the 12-month 
follow-up period, percentages of inpatient (16.40%), emergency room (ER) 
(20.66%), physician office (99.83%), and outpatient visits (99.86%) were also 
calculated. Patient expenditures were found to be $5,498 (SD=$32,411) for 
inpatient, $246 (SD=$899) for ER, $6,724 (SD=$10,694) for physician office and 
$7,201 (SD=$11,407) for outpatient visits. CONCLUSIONS: Results suggest that 
omeprazole is the most frequently prescribed medication after a GERD diagnosis. 
GERD was associated with a high inpatient admission and ER visit rates, which 
translated into a significant cost burden for the health care system.  
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OBJECTIVES: To evaluate total annual all-cause costs of chronic constipation 
(CC) among patients with different health plan benefit designs and assess 
incremental costs of CC in a commercially insured population. METHODS: 
Patients were identified from the HealthCore Integrated Research Database as 
follows: (1) age ≥18 years as of January 1, 2010; (2) continuous eligibility in 2010; 
(3) ≥2 constipation diagnoses (ICD-9-CM: 564.0x) occurring ≥90 days apart or ≥1 
constipation diagnosis plus ≥1 constipation-related prescription occurring ≥90 
days apart. A control group without irritable bowel syndrome, constipation, 
abdominal pain, or bloating was randomly selected using 1:1 matching on basic 
demographic characteristics. Patients were categorized by health plan benefit 
design into non-capitated health maintenance organizations (HMO), preferred 
provider organizations (PPO), Medicare Advantage (MA), and other benefit 
designs. Total all-cause health care costs included pharmacy costs and costs 
from medical services. Generalized linear models were used to evaluate the 
incremental costs attributable to CC. RESULTS: Of 14,854 CC patients and 
controls identified, 71.7% had PPO, 12.0% had non-capitated HMO, 10.2% had MA, 
and 6.1% had other benefit designs. Mean age (±SD) was 58.7 (±20.4) years; 75.4% 
were female. Overall, CC patients had $8,713 (P<0.001) higher unadjusted total 
annual all-cause health care costs versus matched controls; costs were $9,736 
(P<0.001) higher for non-capitated HMO, $8,029 (P<0.001) for PPO, and $11,813 
(P<0.001) for MA. Medical costs were the primary driver of unadjusted all-cause 
costs regardless of benefit design (82%-84% of total costs). This finding remained 
consistent in the overall study population even after adjusting for demographics 
and comorbidities. Total incremental all-cause costs associated with CC were 
$3,508 (P<0.001), with 81% for medical services. CONCLUSIONS: The economic 
burden of CC is substantial in a US commercially insured population. A 
consistent burden was seen across different health plan benefit designs, with 
costs driven by the use of medical services.  
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OBJECTIVES: Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) that 
results from chronic inflammation restricted to all or part of the colon and 
begins in the rectum. UC significantly impact quality of life and accounts for 
substantial costs to the health care system and society. The objective of this 
study was to describe and estimate health care resource utilization in the 
treatment of UC from a health care system perspective. METHODS: A 
retrospective study of the Quebec provincial drug reimbursement program 
(RAMQ) was conducted using a randomly selected group of patients who 
received at least one diagnosis of UC (ICD-9=556.x) between January 1st, 2010 and 
December 31st, 2011, but who did not received a diagnosis of Crohn’s disease 
(ICD-9=555.x). A control group of patients without any diagnosis of UC was 
created on a 1:1 ratio and matched for age and gender. The difference between 
the costs of resources consumed during the 2year study period by the two groups 
(using t-test) provided an estimate of the incremental cost associated with the 
management of UC. RESULTS: A total of 2,975 patients with UC were included in 
the study (mean age=55.5 years, 52% females). During the 2-year study period, 
patients had received a total of 57,264 scripts for anti-inflammatory drugs, 
immunosuppressors and/or anti-TNFα agents. The total cost of medical 
procedures, medications and hospitalizations were higher for UC patients, with 
an annual incremental cost per patient of CAN$370 (95%CI: 331-410), CAN$2,374 
(95%CI: 2135-2613) and CAN$2,795 (95%CI: 2399-3192), respectively. The annual 
difference in direct costs between UC patients and controls was estimated at 
CAN$5,539 (95%CI: 5,036-6,043) per patient. CONCLUSIONS: The present analysis 
illustrates the high cost of treatments, the high frequency of hospitalizations 
resulting in increased hospitalization costs and the substantial economic 
burden, in terms of direct medical costs associated with UC.  
 
PGI11  
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OBJECTIVES: Antiemetic is a drug that is effective against vomiting and nausea. 
The objective of this study is to calculate price trends for individual antiemetic 
and to describe the trends of utilization and spending on antiemetic drugs in the 
U.S. Medicaid program. METHODS: A retrospective descriptive analysis was 
performed using data from the Medicaid database from 1991 through second 
quarter 2011. We extracted the utilization and expenditure data from the 
national Medicaid pharmacy files collected by the Centers for Medicare & 
Medicaid Services. Study drugs include antihistamines (cyclizine, 
dimenhydrinate, buclizine), steroids (dexamethasone, methylprednisolone), 
dopamine antagonists (droperidol, ondansetron, granisetron, palonosetron). 
Total prescriptions reimbursed by Medicaid and total reimbursement cost were 
calculated by adding the data for each antiemetic identified by its NDC. The 
Annual totals of reimbursement per-prescription were calculated as annual total 
reimbursement divided by Annual total number of prescriptions. RESULTS: The 
total number of prescriptions which paid by Medicaid was increased from 
$339,822 in 1991 to $1.0 million in second quarter of 2011. The data shows 80% 
decrease in antiemetic utilization in 1999. The drug Ondansetron has increasing 
trends after 2006 up to about 70% in the first quarter of 2011. The price was in 
increasing rate until 2011. About 100% increase in the price of generic Zofran. 
The average of reimbursement per prescription has increased from $15.22 in 
1991 to $36.90 in 2011. CONCLUSIONS: In the light of this study, more studies are 
needed to create antiemetic guidelines that would help to improve efficacy, 
increase the patients compliance, and decrease the antiemetic costs.  
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OBJECTIVES: To evaluate the cost-effectiveness of linaclotide 290 mcg once daily 
versus lubiprostone 8 mcg twice daily in the treatment of adult patients with 
irritable bowel syndrome with constipation (IBS-C) METHODS: Using model 
inputs derived from published literature, linaclotide Phase III trial data, and a 
physician survey on resource utilization associated with treatment failure, a 
decision-tree model was constructed to estimate outcomes and costs of 
treatment for IBS-C. Response to therapy was defined as (1) a ≥14-point increase 
from baseline in IBS-QOL overall score at Week 12 or (2) one of the top two 
responses (moderately/significantly relieved) on a seven-point IBS symptom 
relief question in ≥2 of 3 months. Patients who do not respond to therapy are 
assumed to fail therapy and accrue costs associated with a treatment failure. 
Model time horizon is aligned with clinical trial duration at 12 weeks. Model 
outputs include number of responders, quality-adjusted life-years (QALYs), total 
costs (including direct and indirect), and incremental cost-effectiveness ratios 
(ICERs). Both one-way and probabilistic sensitivity analyses were conducted. 
RESULTS: Treatment for IBS-C with linaclotide produced more responders than 
lubiprostone for both response definitions (19.3% vs. 13.0% and 61.6% vs. 57.2% 
for IBS-QOL and symptom relief, respectively), lower per-patient costs ($780 vs. 
$870 and $1,014 vs. $1,088), and higher QALYs (0.1924 vs. 0.1917 and 0.1909 vs. 
0.1894, over the 12-week time horizon). Therefore, linaclotide was dominant 
(more effective and less expensive) compared to lubiprostone. Results were 
similar to base-case for most one-way sensitivity analyses. The majority of 1,000 
second order Monte Carlo simulations resulted in linaclotide dominant ICERs for 
both definitions of treatment response. CONCLUSIONS: Linaclotide was found to 
be cost-effective versus lubiprostone for treatment of adult patients with IBS-C.  
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OBJECTIVES: To assess the cost-effectiveness of infliximab as induction therapy 
(3 doses) for the treatment of severe active ulcerative colitis, i.e. exacerbations 
requiring hospitalization in adult patients with an inadequate response to 
conventional therapy including intravenous glucocorticoids, compared with 
surgery (colectomy) in Poland. METHODS: This study used the decision tree 
model which was positively received by NICE and adjusted to Polish settings. 
A214 V A L U E  I N  H E A L T H  1 6  ( 2 0 1 3 )  A 1 - A 2 9 8  
  
 
Efficacy parameters were based on clinical trials: Jarnerot 2005, Sands 2001, 
Lichtiger 1994 and D'Haens 2001. Twelve-month time horizon was developed. 
Cost data specific for the Polish health care system was based on retrospective 
medical record review of patients with ulcerative colitis. Resource use associated 
with the surgery was based on clinical expert opinion. The unit costs of 
treatment were derived from Polish official tariff lists for health care services 
paid by public payer. Average body weight of the patient (60 kg) was based on 
data from registry of patients with Crohn’s disease, assuming the similar nature 
of the disease. RESULTS: Infliximab was associated with a gain of 0.21 quality 
adjusted life years (QALYs) compared with colectomy. Additional costs 
associated with the biological treatment were estimated at 14,793 PLN. 
Incremental cost-utility ratio was estimated at 69,984 PLN/QALY for infliximab 
compared with colectomy. The sensitivity analysis showed a relative consistency 
of results. CONCLUSIONS: The estimated cost per QALY is much below official 
threshold (99,543 PLN/QALY) which indicates that treatment with infliximab is 
cost effective compared with surgical treatment in Polish conditions.  
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OBJECTIVES: Compare the cost-per-remission of adalimumab (ADA) to 
infliximab (IFX) for the treatment of moderately to severely active ulcerative 
colitis (UC) in the Brazilian public health care system (SUS). METHODS: 
Treatment costs considered drug acquisition costs from a public payer 
perspective in Brazil considering an average patient of 80 kg. The cost/vial of IFX 
and ADA were defined by the latest government acquisitions, as published in the 
official website comprasnet.gov.br. The time horizon was defined at 8, 52 and 54 
weeks of treatment. The recommended dose and dosing intervals were 
according to label of each drug. The nnt was calculated based on the clinical 
remission data gathered at week 8 and week 52/54 from the published phase III 
clinical trials of ADA and IFX, ULTRA-2 and ACT I respectively. (Rutgeerts P 2005; 
Sandborn WJ 2012). RESULTS: At week 8, IFX has a treatment cost of R$ 13.652 
with a cost-per-NNT for clinical remission of R$ 54.610 (bio-naive and all 
patients), compared to ADA with a treatment cost of R$ 8.284 and a cost-per-NNT 
for clinical remission of R$ 115.983/patient and R$ 82.845/bio-naive patient. At 
week 52/54, IFX has a treatment cost of R$ 36.406 compared to ADA with R$ 
31.067/R$ R$ 32.102 per patient. Considering the cost-per-NNT for clinical 
remission at week 52/54, ADA has an average cost of R$ 341.735 compared to IFX 
with a cost-per-NNT for clinical remission of R$ 182.032 at week 52/54. 
Considering bio-naive patients, IFX remains with a cost-per-NNT for clinical 
remission of R$ 182.032 compared to ADA with R$ 310.668/R$ 341.735 at week 
52/54. CONCLUSIONS: IFX has a lower number needed to treat and a lower cost-
per-NNT to achieve clinical remission at both week 8 week 52/54 compared with 
ADA in the treatment of moderately to severely active ulcerative colitis, 
independently of patient subgroup.  
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OBJECTIVES: To demonstrate the efficacy, security and effectiveness of tenofovir 
disoproxil fumarate (Viread®) in the treatment of patients with chronic hepatitis 
B (CHB) in Mexico, from the Mexican institutional perspective. METHODS: We 
used decision analysis to calculate the cost-effectiveness of 5 competing 
strategies in CHB treatment, 1) tenofovir DF; 2) Entecavir; 3) Adefovir; 4) 
Lamivudine; and 5) Peginterferon alfa-2a, from the insititutional perspective. A 
Markov model was developed over 40 years’ time horizon. The outcome measure 
was the life years gained (LY). Direct health care cost where used and the 
discount rate was of 5% for cost and life years, also incremental cost 
effectiveness ratio (ICER), sensitivity analyses and probabilistic sensitivity 
analyses were performed. RESULTS: Tenofovir DF had more effectiveness and 
less cost in the treatment of CHB; in the Markov model tenofovir DF had the 
highest life years gained compared with all other therapies under evaluation. 
Tenofovir DF had 15.49LY with a cost of $363,314.84, Entecavir had 15.37LF with a 
cost of $435,849.99, Adefovir had 14.89LY with a cost of $487,457.55, Lamivudina 
had 13.84LY with a cost of $498,603.87 and Peginterferon alfa-2a had 13.56LY with 
a cost of $406,795.25, hence all the therapies had an ICER dominated by tenofovir 
DF in all the scenarios. The sensitivity analyses proved that tenofovir DF was 
cost effective compared to all other therapies under evaluation in the treatment 
of CHB patients in Mexico. According to the probabilistic sensitivity analyses, the 
likelihood of tenofovir DF to be cost effective is 88% under the willingness-to-pay 
threshold in Mexico. CONCLUSIONS: There is evidence from the clinical and the 
cost effectiveness study that the use of tenofovir DF in the treatment of patients 
with CHB is cost effective, and must be considered as first option in the 
treatment of patients with CHB diagnosis in Mexico.  
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OBJECTIVES: In observational studies and randomized trials of patients with 
hepatitis C infection, higher medication adherence is associated with improved 
clinical outcomes. We evaluated the impact of adherence on long-term outcomes 
and costs in patients with genotype 1 chronic hepatitis C (CHC) receiving 
peginterferon and ribavirin (PEG-RBV). METHODS: We utilized a cohort Markov 
model describing the natural history of hepatitis C infection in a population of 50 
year-old, treatment-experienced subjects to evaluate transitions between CHC, 
compensated cirrhosis, decompensated cirrhosis, hepatocellular carcinoma, liver 
transplant, liver transplant survivor, and death. Using previously published data 
from the Hepatitis C Antiviral Long-term Treatment against Cirrhosis trial, we 
modeled four levels of medication adherence: >80% PEG-RBV, >80% PEG/<80% 
RBV, <80% PEG/>80% RBV, and <80% PEG-RBV. We calculated the difference in 
total liver-related health care costs between patients in the lowest versus each 
higher level of adherence following a hypothetical nursing-based intervention 
program, and performed probabilistic sensitivity analysis to evaluate uncertainty 
in our results. RESULTS: Over a lifetime horizon, comparing patients of highest 
versus lowest adherence levels, we found the following reductions in liver-
related events: 9.9% compensated cirrhosis, 4.7% decompensated cirrhosis, 1.4% 
hepatocellular carcinoma, and 0.5% liver transplant. Among the various 
scenarios of medication adherence, the difference in total discounted treatment 
and medication costs ranged from $12,820 to $62,690. Thus, an intervention that 
could, on average, improve adherence by 20% would lead to cost offsets of $29, 
850 and improvement in QALYs of 0.378. The 95% confidence ranges from 
probabilistic sensitivity analysis were $18,790-$35,600 and -0.387 to 0.810 QALYs. 
CONCLUSIONS: This model-based analysis demonstrates that increased patient 
adherence may result in improved outcomes and reduced costs. Future research 
should focus on the design of targeted interventions to implement these 
findings.  
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OBJECTIVES: To demonstrate the efficacy, security and effectiveness of 
alverine/simethicone (Meteospasmyl®) in the treatment of patients with irritable 
bowel syndrome (IBS) in Mexico, from institutional perspective. METHODS: We 
used decision analysis to calculate the cost-effectiveness of 3 competing 
strategies in IBS treatment, 1) alverine/simethicone (A/S); 2) pinaverium bromide 
(PB); and 3) tegaserod (T). A decision tree was developed over 1 month time 
horizon, and then a Markov model was designed over 13 months, this model was 
carry out in two scenarios, the first Markov model studies the patient treatment 
only with one drug therapy, the second one analyses the patient using a switch 
of treatment if the patient didn’t respond to the first option. The outcome 
measure was the global improvement of the symptoms and the time without the 
disease respectively. Direct health care cost where used, also incremental cost 
effectiveness ratio (ICER), sensitivity analyses and probabilistic sensitivity 
analyses was performed. RESULTS: A/S had more effectiveness and less cost in 
the treatment of IBS; in the decision tree, for every 1% of patients with clinical 
response using A/S, it must be pay an average of $3048.15, in the Markov model 
A/S compared to PB was a dominant strategy; T was extended dominated in both 
analyses from the institutional perspective. The sensitivity analyses proved that 
A/S was cost effective compared to PB and T in the treatment of IBS patients in 
Mexico. According to the probabilistic sensitivity analyses, the likelihood of A/S 
to be cost effective is 90% under the willingness-to-pay threshold in Mexico. 
CONCLUSIONS: There is evidence from the clinical and the cost effectiveness 
study that the use of A/S in the treatment of patients with IBS is cost effective, 
and must be considered as first option in the treatment of patients with IBS 
diagnosis in Mexico.  
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OBJECTIVES: Recent advances in diagnostic imaging technology have been 
followed by an increased incidence of asymptomatic pancreatic neoplasms. 
Recommended clinical approaches to continued monitoring vary in frequency, 
invasiveness and cost. This study's objective is to compare the risks and cost 
implications associated with annual computed tomography (CT), empiricism 
(watchful waiting), endoscopic ultrasound (EUS) and magnetic resonance 
imaging (MRI) screening. METHODS: Cost and accuracy information was 
obtained from published peer-reviewed journal articles. Empiricism serves as a 
baseline comparison of these procedures and includes the cost of one annual 
physician visit. Incremental Cost Effectiveness Ratios (ICERs) were calculated, 
(procedure cost/detection rate accuracy) and compared across diagnostic testing 
procedures. Risk was defined as the chance of missed detection due to less 
accurate imaging or lack of screening. RESULTS: Costs for empiricism ($82) were 
minimal when compared to CT ($196), EUS ($671) and MRI ($363). Although 
empiricism was the least expensive monitoring strategy, it was associated with 
the highest risk of undetected metastasizings. Of the diagnostic options, CT had 
